<![CDATA[Introduction: Diabetic retinopathy is a complication of diabetes and is one of the leading causes of blindness. Diabetic retinopathy occurs when the blood vessels in the retina are damaged and this is associated with hyperglycemia and other conditions in diabetes. Bevacizumab is used to treat diabetic retinopathy and other diseases that affect the retina. Bevacizumab injection is used to prevent vision loss by blocking the abnormal development of blood vessels in the retina. This study aims to examine the characteristics and visual acuity of diabetic retinopathy patients before and after bevacizumab injection.Methods: This type of research is a retrospective descriptive conducted by collecting data from medical records that meet the inclusion criteria. Data were collected from January 1, 2019 to December 31, 2019, totaling 69 eyes from 40 patients as the study sample.Results: The results showed that most of the eyes had NPDR, which amounted to 55 (80%) eyes. Prior to bevacizumab injection, visual acuity of 6/6 – 6/18 was 18%, visual acuity of 6/19 – 6/60 was 37.7% and visual acuity of 5/60 – 1/∞ was 43.5%. After injection of bevacizumab, visual acuity of 6/6 – 6/18 was 27.5%, visual acuity of 6/19 – 6/60 was 42% and visual acuity of 5/60 – 1/∞ was 30.4%. In this study, eyes that did not experience changes in visual acuity were 52.2%, eyes that had improved 34.8% and eyes that had decreased 13%.Conclusion: In conclusion, after the injection of bevacizumab, the eyes that did not experience changes in visual acuity were more after 1 month follow-up, namely 52.2%.]]>
Copyrights © 2021
